Nyvepria®

Biosimilar medicine authorized by the AEMPS

Nyvepria®

ACTIVE PRINCIPLE:
Pegfilgrastim

DATE:
08/01/2021

MORE INFO

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

PRIVACY POLICY

SUBSCRIBE